Osteoporosis International

, Volume 19, Issue 3, pp 339–348 | Cite as

Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies

  • I. Byrjalsen
  • D. J. Leeming
  • P. Qvist
  • C. Christiansen
  • M. A. Karsdal
Original Article



Bone collagen maturation may be important for anti-fracture efficacy as the reduction in risk is only partly explained by a concomitant increase in BMD during anti-resorptive therapy. Different treatments caused diverse profiles in bone collagen degradation products, which may have implications for bone quality.


The aim of the present study was to evaluate the effect of different anti-resorptive treatments on bone collagen maturation measured as the ratio between the degradation products of newly synthesized and mature isomerized C-telopeptides of type I collagen.


Participants were from cohorts of healthy postmenopausal women participating in double blind, placebo-controlled 2-year studies of alendronate, ibandronate, intranasal hormone replacement therapy (HRT), oral HRT, transdermal HRT, or raloxifene (n = 427). The non-isomerized ααCTX and isomerized ββCTX were measured in urine samples obtained at baseline, and after 6, 12, and 24 months of therapy.


Bone collagen maturation measured as the ratio between ααCTX and ββCTX showed that bisphosphonate treatment induced a collagen profile consistent with an older matrix with a 52% (alendronate) and 38% (ibandronate) reduction in the ratio between the two CTX isoforms vs. 3% and 15% with HRT or raloxifene, respectively.


Anti-resorptive treatments had different effects on the endogenous profile of bone collagen maturation. Whether that effect on bone collagen has an impact on bone strength independent on the treatment-dependent effect on BMD should be investigated.


Bone quality Bone turnover Collagen Fracture risk Matrix proteins 



Conflict of Interest

Inger Byrjalsen, Diana J Leeming, and Per Qvist are employees of Nordic Bioscience A/S, and Per Qvist , Claus Christiansen, and Morten A Karsdal are stock owners of Nordic Bioscience A/S.


  1. 1.
    Dempster DW (2006) Anatomy and functions of the adult skeleton. In: Favus MJ (founding ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 6th edn. American Society for Bone and Mineral Research, Washington, USA, pp 7–11Google Scholar
  2. 2.
    Takahashi H, Epker B, Frost HM (1964) Resorption precedes formative activity. Surg Forum 15:437–438PubMedGoogle Scholar
  3. 3.
    Hattner R, Epker BN, Frost HM (1965) Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 206:489–490PubMedCrossRefGoogle Scholar
  4. 4.
    Parfitt AM (1982) The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 4:1–6PubMedCrossRefGoogle Scholar
  5. 5.
    Martin TJ (1993) Hormones in the coupling of bone resorption and formation. Osteoporos Int 3(Suppl 1):121–125PubMedCrossRefGoogle Scholar
  6. 6.
    Nakamura M, Udagawa N, Matsuura S et al (2003) Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology 144:5441–5449PubMedCrossRefGoogle Scholar
  7. 7.
    Rodan GA (1991) Mechanical loading, estrogen deficiency, and the coupling of bone formation to bone resorption. J Bone Miner Res 6:527–530PubMedCrossRefGoogle Scholar
  8. 8.
    Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536PubMedCrossRefGoogle Scholar
  9. 9.
    Ravn P, Hosking D, Thompson D et al (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368PubMedCrossRefGoogle Scholar
  10. 10.
    Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244PubMedCrossRefGoogle Scholar
  11. 11.
    Ravn P, Thompson DE, Ross PD et al (2003) Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33:150–158PubMedCrossRefGoogle Scholar
  12. 12.
    Odvina CV, Zerwekh JE, Rao DS et al (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRefGoogle Scholar
  13. 13.
    Fledelius C, Johnsen AH, Cloos PA et al (1997) Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 272:9755–9763PubMedCrossRefGoogle Scholar
  14. 14.
    Cloos PA, Lyubimova N, Solberg H et al (2004) An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone. Clin Lab 50:279–289PubMedGoogle Scholar
  15. 15.
    Garnero P, Borel O, Gineyts E et al (2006) Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38:300–309PubMedCrossRefGoogle Scholar
  16. 16.
    Viguet-Carrin S, Roux JP, Arlot ME et al (2006) Contribution of the advanced glycation end product pentosidine and maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39:1073–1079PubMedCrossRefGoogle Scholar
  17. 17.
    Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822PubMedCrossRefGoogle Scholar
  18. 18.
    Miller PD, Siris ES, Barrett-Connor E et al (2002) Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Mineral Res 17:2222–2230CrossRefGoogle Scholar
  19. 19.
    Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRefGoogle Scholar
  20. 20.
    Hui SL, Slemenda CW, Johnston CC Jr (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804–1809PubMedCrossRefGoogle Scholar
  21. 21.
    Faulkner KG (2000) Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 15:183–187PubMedCrossRefGoogle Scholar
  22. 22.
    Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19:330–337PubMedCrossRefGoogle Scholar
  23. 23.
    Riis B, Ise J, von Stein T et al (2001) Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Mineral Res 16:1871–1878CrossRefGoogle Scholar
  24. 24.
    Nielsen TF, Ravn P, Bagger YZ et al (2004) Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study. Osteoporos Int 15:168–174PubMedCrossRefGoogle Scholar
  25. 25.
    Warming L, Ravn P, Nielsen T et al (2004) Safety and efficacy of drospironone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 7:103–111PubMedCrossRefGoogle Scholar
  26. 26.
    Warming L, Ravn P, Christiansen C (2005) Levonorgestrel and 17β-estradiol given transdermally for the prevention of postmenopausal osteoporosis. Maturitas 50:78–85PubMedCrossRefGoogle Scholar
  27. 27.
    Delmas PD, Bjarnason NH, Mitlak BH et al (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647PubMedCrossRefGoogle Scholar
  28. 28.
    Rosenquist C, Fledelius C, Christgau S et al (1998) Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44:2281–2289PubMedGoogle Scholar
  29. 29.
    Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643–2658PubMedCrossRefGoogle Scholar
  30. 30.
    McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMedCrossRefGoogle Scholar
  31. 31.
    Reid IR, Brown JP, Burckhardt P et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661PubMedCrossRefGoogle Scholar
  32. 32.
    Watts NB, Cooper C, Lindsay R et al (2004) Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate. J Clin Densitom 7:255–261PubMedCrossRefGoogle Scholar
  33. 33.
    Sarkar S, Mitlak BH, Wong M et al (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10PubMedCrossRefGoogle Scholar
  34. 34.
    Cummings SR, Karpf DB, Harris F et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289PubMedCrossRefGoogle Scholar
  35. 35.
    Weinstein RS (2000) True strength. J Bone Miner Res 15:621–625PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2007

Authors and Affiliations

  • I. Byrjalsen
    • 1
  • D. J. Leeming
    • 1
  • P. Qvist
    • 1
  • C. Christiansen
    • 1
  • M. A. Karsdal
    • 1
  1. 1.Nordic Bioscience A/SHerlevDenmark

Personalised recommendations